Single-organelle cortical transport imaging
The two-photon assay follows BDNF-containing granules in cortico-cortical projections at substantially higher spatiotemporal resolution than the prior in vivo work described by the paper.
↳ Results, Fig. 1
Impairments in axonal transport have been implicated in the pathogenesis of tauopathies, including frontotemporal dementia and Alzheimer's disease, yet the underlying mechanisms and reversibility of these deficits are largely unknown. In particular, the impacts of tau mutations, phosphorylation and aggregation on axonal transport in vivo remain controversial. By using two-photon imaging of axonal transport of BDNF granules in the mouse cortex, we reveal that deficits in axonal transport arise in vivo at early stages of tau pathology, preceding tangle formation and neuronal death. Mechanistically, these impairments are caused by the enlargement of tau envelopes on microtubules, which act as functional barriers for transport. Crucially, these deficits are reversed by inhibiting MAPK p38α. Together, our work demonstrates that tau pathology causes reversible deficits in axonal transport in vivo, posing the basis for pharmacological interventions to restore the physiological flux of axonal organelles and cargoes in tauopathies.
deficits in axonal transport arise in vivo at early stages of tau pathology, preceding tangle formation and neuronal death.
mouse-level evidence supports an early model-specific deficit, but very small female cohorts limit precision and generalisability
these deficits are reversed by inhibiting MAPK p38α.
paired inhibitor experiments improve selected transport measures, though rescue is partial and treatment order is fixed
tau envelopes function as obstacles for axonal transport
colocalisation, pause association, and correlative microscopy do not independently manipulate envelope size or establish causation
the activity of SB-239063 on axonal transport is largely dependent on the reduction of P301L tau phosphorylation levels.
phosphomutants are informative, but the inhibitor comparison being explained is non-significant and nested observations are not modeled
Derived from the full evaluation — not a separate score.
Strengths
The two-photon assay follows BDNF-containing granules in cortico-cortical projections at substantially higher spatiotemporal resolution than the prior in vivo work described by the paper.
↳ Results, Fig. 1
Doxycycline suppression, the rTg21221 WT-tau line, phosphomutant constructs, and two p38 inhibitors test complementary parts of the proposed pathway.
↳ Figs. 2–6; Extended Data Fig. 1g–j
The Discussion addresses contradictory transport studies, divergent taxol findings, incomplete rescue, and the possibility that the observed structures are small pathological aggregates rather than canonical envelopes.
↳ Discussion, both subsections
Limitations
Figs. 5–7 conduct inference on neurons or axons nested within three to five neuronal preparations; plotting preparation means does not account for that dependence.
↳ Figs. 5c,d, 6b,c and 7c–e,i
The envelope-obstacle claim is largely correlational, while phosphorylation dependence and envelope-size restoration are stated despite non-significant direct comparisons in Figs. 6 and 7.
↳ Abstract; Figs. 6b,c and 7h,i; Discussion
Central imaging comparisons use three to four mice per group and predominantly or exclusively female cohorts, limiting precision and generalisability despite paired designs.
↳ Figs. 2d, 3d and 4c,d legends
The strongest contribution is the in vivo observation that cortical BDNF-granule transport is impaired early in rTg4510 mice and improves on selected measures after p38 inhibition. Animal-level aggregation, paired imaging, genetic controls, and a second inhibitor support that direction of effect. The quality score is constrained by neuron- and axon-level inference across a small number of culture preparations, which weakens the phosphorylation and envelope mechanism. The abstract and Discussion also present the envelope mechanism and rescue more definitively than the correlational and partly non-significant evidence warrants.
Nabu’s assessment, alongside the field’s view.
Are you an author of this paper?
The study meaningfully extends prior work by measuring BDNF-granule transport at single-organelle resolution in association-cortex projections and connecting early deficits to p38 inhibition. Its advance is strongest for the in vivo transport observation, while the detailed envelope mechanism remains less secure.
deficits in axonal transport arise in vivo at early stages of tau pathology
Animal-level aggregation, paired imaging, genetic controls, two inhibitors, and blinded analysis support the in vivo arm. Central culture-mechanism tests nevertheless use neurons or axons as inferential observations despite clustering within three to five preparations, so the serious pseudoreplication ceiling binds.
Lighter ‘X’ symbols represent the averages per preparation.
The progression from assay validation to in vivo rescue and cellular mechanism is easy to follow. Causal envelope language and statements of restoration or phosphorylation dependence are stronger than the correlational or non-significant comparisons support.
these impairments are caused by the enlargement of tau envelopes
The paper engages conflicting in vivo transport findings, prior p38 studies, tau-envelope literature, and the taxol discrepancy. It acknowledges incomplete rescue and structural uncertainty but gives less attention to female-only central imaging, small animal samples, and model-specific limits on extrapolation to AD.
we cannot exclude that they may correspond to small pathological aggregates
Lower confidence on Positioning — domain match limited.
Caveats4 of 4 checks
The reported numbers and statistics are consistent with the stated results.
Track selection is described differently in the legends and Methods, one comparison has two differently reported P values, and an in vivo efficacy statement cites cultured-neuron experiments.
Ethics approval: declared · Preregistration: not stated · Data availability: declared
83 references in manuscript 81 of 81 checkable references found in an index 2 have no canonical index record — counted, but not index-checkable 3 references confirmed by manual review
References not verified automatically are resolved manually within 24 hours.
No retraction or expression of concern found in Crossref (includes Retraction Watch).
Sources: Crossref (incl. Retraction Watch) ✓
The primary claim is demonstrated in a tauopathy mouse model and cultured neurons under controlled laboratory conditions, with no human or clinical evidence presented.
“posing the basis for pharmacological interventions to restore the physiological flux of axonal organelles and cargoes in tauopathies”
The paper names a real-world use of its findings, pharmacological intervention to restore axonal transport in tauopathies, but does not specify who would act on them.
Drug developers and neurologists could advance p38α inhibitors such as neflamapimod as early-stage treatments for tauopathies that restore axonal transport.
The findings rest on mutant-tau mouse models and acute imaging endpoints, so human trials must still show that p38α inhibition restores transport and slows clinical progression.
Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3
AI-generated, human-governed. Something look off? Contact us to request a review.
Keep reading
Other papers Nabu has evaluated blind, starting with the same field.
2026 · Neurology and psychiatry
aggregates enriched during the growth phase downregulated homeostatic microglial markers and induced TLR4-mediated microglial activation, cytokine production, and complement activation, leading to synaptic engulfment and severe disruption of neuronal activity
Tentative2026 · Basic medicine
even brief tau oligomer exposure induces lasting bipartite synapse dysfunction and presenting a timeline of progressive pre- and post-synaptic degeneration.
Tentative